MedPath

Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

First Posted Date
2025-05-14
Last Posted Date
2025-05-14
Lead Sponsor
Allist Pharmaceuticals, Inc.
Target Recruit Count
380
Registration Number
NCT06970639
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangdong, Guangzhou, China

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Phase 1
Not yet recruiting
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
First Posted Date
2025-05-14
Last Posted Date
2025-05-14
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
21
Registration Number
NCT06969612

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3
Not yet recruiting
Conditions
Breast Neoplasms
Triple Negative Breast Neoplasms
HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Drug: Rescue Medication
First Posted Date
2025-05-13
Last Posted Date
2025-05-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
2400
Registration Number
NCT06966700

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

Phase 2
Not yet recruiting
Conditions
Esophageal Cancer Stage III
Interventions
First Posted Date
2025-05-11
Last Posted Date
2025-05-11
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
40
Registration Number
NCT06965829
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Completed
Conditions
Triple Negative Breast Cancer
Interventions
First Posted Date
2025-05-11
Last Posted Date
2025-05-16
Lead Sponsor
Ziauddin University
Target Recruit Count
54
Registration Number
NCT06965361
Locations
🇵🇰

Shamim, Karachi, Sindh, Pakistan

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Phase 2
Terminated
Conditions
Ovarian Neoplasms
Interventions
First Posted Date
2025-05-09
Last Posted Date
2025-05-09
Lead Sponsor
Tesaro, Inc.
Target Recruit Count
36
Registration Number
NCT06964165
Locations
🇪🇸

GSK Investigational Site, Pamplona, ES, Spain

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

First Posted Date
2025-05-02
Last Posted Date
2025-05-02
Lead Sponsor
Allist Pharmaceuticals, Inc.
Target Recruit Count
300
Registration Number
NCT06956001
Locations
🇨🇳

Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences, BeiJing, Beijing, China

🇨🇳

Shandong Tumor Hospital, Shandong, Jinan, China

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

First Posted Date
2025-05-01
Last Posted Date
2025-05-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1123
Registration Number
NCT06952504

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Phase 1
Not yet recruiting
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
First Posted Date
2025-04-27
Last Posted Date
2025-04-27
Lead Sponsor
Jemincare
Target Recruit Count
72
Registration Number
NCT06946927
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Not yet recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2025-04-27
Last Posted Date
2025-05-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
76
Registration Number
NCT06946797
Locations
🇵🇱

Local Institution - 0079, Łódź, Łódzkie, Poland

🇧🇷

Local Institution - 0041, Brasilia, Distrito Federal, Brazil

🇺🇸

Local Institution - 0032, Anchorage, Alaska, United States

and more 45 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy